Core Viewpoint - Mesa Laboratories, Inc. is set to release its financial results for the third quarter of fiscal year 2025 on February 4, 2025, at 8:00 A.M. Eastern time [1] Company Overview - Mesa Laboratories, Inc. is a global leader in designing and manufacturing life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries [2] - The company provides products and services aimed at ensuring product integrity, enhancing patient and worker safety, and improving quality of life globally [2]

Revenue Growth - For the first half of fiscal year 2025, revenues increased by 11.7% to $116,003, driven primarily by the acquisition of GKE, which contributed $12,117[106] - Organic revenues growth was 0.1%, with a notable 25.0% increase from the Biopharmaceutical Development division, while Clinical Genomics experienced a decline of 20.8% due to economic and regulatory challenges[106] - Revenues for the three months ended September 30, 2024, increased by 8.8% to $57,833 million compared to $53,165 million for the same period in 2023[113] - Total revenues for the three months ended September 30, 2024, showed a growth of 8.8%, compared to a decline of 9.5% in the same period of 2023[169] - Organic revenues growth for the total company was 0.1% for the six months ended September 30, 2024, compared to a decline of 5.0% in the same period of 2023[169] Segment Performance - The Sterilization and Disinfection Control division's revenues increased by 30.0% to $22,205 million for the three months ended September 30, 2024, compared to $17,080 million in the same period last year[115] - The Clinical Genomics division's revenues decreased by 26.0% to $11,499 million for the three months ended September 30, 2024, down from $15,549 million in the prior year[118] - The Biopharmaceutical Development division's revenues increased by 28.9% to $11,867 million for the three months ended September 30, 2024, compared to $9,207 million in the same period last year[121] - Calibration Solutions division's revenues increased by 8.2% to $12,262 million for the three months ended September 30, 2024, compared to $11,329 million in the prior year[125] - The Sterilization and Disinfection Control segment reported a total revenue growth of 30.0% for the three months ended September 30, 2024, while organic revenue growth was -4.3%[168] - The Biopharmaceutical Development segment experienced a revenue decline of 26.0% for the three months ended September 30, 2024[169] Profitability and Income - Gross profit as a percentage of revenues improved by 1.7 percentage points to 62.7%, attributed to lower amortization of intangible expenses and a margin contribution of 62.3% from the GKE acquisition[107] - Operating income reached $9,088, an increase of $9,812 compared to the prior year, with GKE contributing $4,533 to consolidated operating income[108] - Net income for the three months ended September 30, 2024, was $3,428 million, a significant increase of 378.7% from a net loss of $1,230 million in the prior year[113] Operating Expenses - Operating expenses declined slightly despite a revenue increase of 11.7%, aided by lower amortization expenses from the Clinical Genomics division[108] - Operating expenses decreased by 0.7% to $31,947 million for the three months ended September 30, 2024, compared to $32,169 million in the same period last year[127] - Selling expenses increased by 2.1% to $9,849 million for the three months ended September 30, 2024, compared to $9,650 million in the prior year[129] - General and administrative expenses decreased by 0.4% to $17,464 million for the three months ended September 30, 2024, compared to $17,526 million in the same period last year[131] - Research and development expenses are primarily driven by labor costs and third-party consultant fees, impacting overall financial performance[133] - Research and development expenses decreased by 7.2% to $4,634 for the three months ended September 30, 2024, and by 4.4% to $9,369 for the six months ended September 30, 2024, compared to the prior year periods[134] Financial Position and Cash Flow - Net cash provided by operating activities was $15,704 for the six months ended September 30, 2024, a decrease of $4,011 compared to $19,715 for the same period in 2023[159] - Working capital was $(45,252) as of September 30, 2024, compared to $65,040 as of March 31, 2024, primarily due to the current portion of the Notes being due within 12 months[146] - Cash used in financing activities was $17,719 for the six months ended September 30, 2024, compared to $15,079 for the same period in 2023[162] - The company expects to incur cash interest expense of approximately $7,300 within the next twelve months related to the Credit Facility[151] - The company plans to use cash on hand, draws against the Revolver, and cash generated from operating activities to fund the $101,250 due on the Notes and Term Loan within the next 12 months[152] Acquisitions and Future Commitments - The company acquired GKE for $87,187, net of cash and financial liabilities acquired, during fiscal year 2024[145] - The company agreed to pay approximately $9,700 million to GKE sellers in April 2025 as part of the GKE acquisition, pending adjustments for potential indemnification losses[164] - For the Belyntic acquisition, the company will pay $1,500 million to sellers if specified patents are issued, with an estimated fair value of remaining contingent consideration at $650 million as of September 30, 2024[165] Economic Factors - The impact of foreign currency fluctuations on reported revenues and expenses remains a significant factor in financial performance[109] - The company faces exchange rate risks, particularly in the Biopharmaceutical Development division, which incurs significant expenses in Swedish Krona while most revenue contracts are in USD and euros[170] - Inflation has not significantly impacted the company's financial statements recently, as cost increases have been offset by annual price increases[172] - The company estimates that a 1 percentage point increase in interest rates would result in approximately $920 million of additional cash interest expense per year[171] Operational Efficiency - The company aims to enhance operating efficiency through its Mesa Way system, focusing on customer-centric improvements and lean-based methodologies[101] - The company continues to pursue growth through both organic means and acquisitions, emphasizing the importance of integrating new businesses effectively[100]

Exhibit 99.1 Mesa Labs Announces Second Quarter Results Lakewood, Colorado, November 7, 2024 – Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its second fiscal quarter ("2Q25") ended September 30, 2024 (amounts in thousands). Second quarter FY 2025 compared to second quarter FY 2024: ● Revenues increased 8.8% ● Non-GAAP core organic revenues1 decline was 2.8% ● Operating income inc ...

LAKEWOOD, Colo., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its second fiscal quarter (“2Q25”) ended September 30, 2024 (amounts in thousands). Second quarter FY 2025 compared to second quarter FY 2024: Revenues increased 8.8%Non-GAAP core organic revenues¹ decline was 2.8%Operating income increased 5,947% to $3,508 Non-GAAP adjusted operating ...

Mesa Labs (MLAB) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. The upward trend in estimate revisions for this quality control instruments and disposable products maker reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation b ...

Mesa Labs (MLAB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a changing e ...

LAKEWOOD, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter ("1Q25") ended June 30, 2024 (amounts in thousands). First quarter FY 2025 compared to first quarter FY 2024: Revenues increased 14.9% Non-GAAP core organic revenues1 growth was 3.0% Operating income increased 940% Non-GAAP adjusted operating income excluding u ...

Table of Contents Title of each class Trading SymbolName on each exchange on which registered Common Stock, no par value MLAB The Nasdaq Stock Market LLC Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated filer ☐Smaller reporting company ☐ Emerging growth company ☐ United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION RE ...

Exhibit 99.1 Mesa Labs Announces First Quarter Results Lakewood, Colorado, August 5, 2024 – Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter ("1Q25") ended June 30, 2024 (amounts in thousands). First quarter FY 2025 compared to first quarter FY 2024: ● Revenues increased 14.9% ● Non-GAAP core organic revenues1 growth was 3.0% ● Operating income increased 940% ...

Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. For more information about the Company, please visit its website at www.mesalabs.com Lakewood, Colo, July 08, 2024 (GLOBE NEWSWIRE) - ...